International Fund for Regenerative Medicine Project (IFRM)
Funding Opportunity Purpose
The Foundation for Regenerative Medicine (FRM) accepts applications to support research studies aimed at furthering the field of regenerative medicine (RM). These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness.
Toward these ends, the FRM will consider applications for late-stage preclinical research studies involving adult stem cells in the context of generating or supplementing the necessary evidence for clinical development, including, but not limited to, the submission of an Investigational New Drug (IND) or Investigational New Device Exemption (IDE) package; or to support such research conducted under an authorized IND or IDE.
The applications of advisory board members of FRM are prioritized. You can apply for joining the advisory board here.
Key Dates
Posted Date
September 06, 2018
Open Date (Earliest Submission Date)
September 16, 2018
Application Due Date(s)
November 16, 2018, by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review
January 2019
Advisory Council Review
January 2019
Earliest Start Date
April 2019
Expiration Date
November 17, 2018
Award Information
Award Budget
The total budget (Federal award and non-Federal matching contributions) should reflect the actual needs of the proposed project. While annual project budgets should reflect the actual costs anticipated in each year, the Federal share of this award must not exceed $250,000 in direct costs per year.
The recipient is required to provide at least a 1:1 match of the Federal funds requested (for Direct and Indirect/F&A costs) in the form of non-Federal contributions.
Award Project Period
The scope of the proposed project should determine the project period. The maximum project period will be up to 2 years.
Section III. Eligibility Information
1. Eligible Applicants
Eligible Organizations
Higher Education Institutions
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Letter of Intent
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the of application, prospective applicants are asked to submit a letter of intent that includes the following information:
Foundation for Regenerative Medicine
Nicole Gann, Executive Director
711 E Chapman Ave
Orange, CA 92866 , USA
Telephone: +1 (888) 712-3123
Email: NGANN@REGENERATIVEFOUNDATION.org
The Foundation for Regenerative Medicine (FRM) accepts applications to support research studies aimed at furthering the field of regenerative medicine (RM). These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness.
Toward these ends, the FRM will consider applications for late-stage preclinical research studies involving adult stem cells in the context of generating or supplementing the necessary evidence for clinical development, including, but not limited to, the submission of an Investigational New Drug (IND) or Investigational New Device Exemption (IDE) package; or to support such research conducted under an authorized IND or IDE.
The applications of advisory board members of FRM are prioritized. You can apply for joining the advisory board here.
Key Dates
Posted Date
September 06, 2018
Open Date (Earliest Submission Date)
September 16, 2018
Application Due Date(s)
November 16, 2018, by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review
January 2019
Advisory Council Review
January 2019
Earliest Start Date
April 2019
Expiration Date
November 17, 2018
Award Information
Award Budget
The total budget (Federal award and non-Federal matching contributions) should reflect the actual needs of the proposed project. While annual project budgets should reflect the actual costs anticipated in each year, the Federal share of this award must not exceed $250,000 in direct costs per year.
The recipient is required to provide at least a 1:1 match of the Federal funds requested (for Direct and Indirect/F&A costs) in the form of non-Federal contributions.
Award Project Period
The scope of the proposed project should determine the project period. The maximum project period will be up to 2 years.
Section III. Eligibility Information
1. Eligible Applicants
Eligible Organizations
Higher Education Institutions
- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education
- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Small Businesses
- For-Profit Organizations (Other than Small Businesses)
- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized)
- U.S. Territory or Possession
- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Faith-based or Community-based Organizations
- Regional Organizations
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Letter of Intent
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the of application, prospective applicants are asked to submit a letter of intent that includes the following information:
- Descriptive title of proposed activity
- Name(s), addresses, and telephone number(s) of the PD(s)/PI(s)
- Names of other key personnel
- Participating institution(s)
- Number and title of this funding opportunity
Foundation for Regenerative Medicine
Nicole Gann, Executive Director
711 E Chapman Ave
Orange, CA 92866 , USA
Telephone: +1 (888) 712-3123
Email: NGANN@REGENERATIVEFOUNDATION.org